Viscosupplementation Market Report 2026

The viscosupplementation market size has grown rapidly in recent years. It will grow from $4.5 billion in 2025 to $4.97 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to rising prevalence of osteoarthritis, increasing geriatric population, advancements in joint care therapies, growing awareness of viscosupplementation, expanding orthopedic healthcare infrastructure.

The viscosupplementation market size is expected to see rapid growth in the next few years. It will grow to $7.34 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to adoption of regenerative medicine, integration of digital health monitoring, development of novel hyaluronic acid formulations, expansion of ambulatory surgical centers, rising investments in outpatient orthopedic procedures. Major trends in the forecast period include minimally invasive joint therapies, regenerative medicine integration, personalized osteoarthritis treatment, injectable hyaluronic acid innovations, outpatient orthopedic procedures.

The growing prevalence of osteoarthritis is expected to drive the expansion of the viscosupplementation market in the coming years. Osteoarthritis, a degenerative joint disease and a common form of arthritis, occurs when the joints, particularly in the hips, knees, and hands, begin to deteriorate. Viscosupplementation treatments help alleviate pain and facilitate smooth bone movement by injecting hyaluronic acid directly into the joints, reducing pain and improving joint functionality. For example, in August 2023, the Institute for Health Metrics and Evaluation (IHME), a U.S.-based nonprofit global health research center, reported that by 2050, osteoarthritis of the knee is expected to increase by 75%, and osteoarthritis of the hand by 50%. Therefore, the rising prevalence of osteoarthritis is driving the growth of the viscosupplementation market.

Leading companies in the viscosupplementation market are focusing on developing innovative products, such as resorbable hyaluronic acid scaffolds, to improve joint lubrication, promote tissue regeneration, and offer long-lasting relief from osteoarthritis symptoms, thereby enhancing patient outcomes and broadening treatment options. A resorbable hyaluronic acid scaffold is a biocompatible, biodegradable structure made from hyaluronic acid (HA), a naturally occurring polysaccharide in connective tissues. For instance, in May 2023, Anika Therapeutics, Inc., a U.S.-based company specializing in orthopedics, launched Hyalofast, a single-stage, off-the-shelf, resorbable hyaluronic acid scaffold for cartilage repair. Hyalofast provides a hyaluronic acid-based solution for joint preservation, potentially offering an alternative to more invasive surgical procedures.

In August 2025, Ono Pharmaceutical Co., Ltd., a Japan-based provider of pharmaceuticals and medical products, partnered with Seikagaku Corporation to co-develop and market Gel-One, a hyaluronic acid-based viscosupplement for osteoarthritis. Through this partnership, the companies aim to expand their presence in the Japanese viscosupplementation market by combining Seikagaku's product development and manufacturing expertise with Ono's marketing and distribution network. Seikagaku Corporation is a Japan-based developer and manufacturer of hyaluronic acid therapeutics, including injectable viscosupplements for joint health.

Major companies operating in the viscosupplementation market are Seikagaku Corporation, Anika Therapeutics Inc., Bioventus LLC, Zimmer Biomet, Johnson & Johnson Services Inc., Aptissen S.A., Smith & Nephew Plc., Flexion Therapeutics Inc., Regen Lab SA, OrthogenRx Inc., Fidia Farmaceutici S.P.A, Ferring Pharmaceuticals, Laboratoires VIVACY, Allergan, Hyalgan, Synvisc, Euflexxa, Sanofi S.A., Wellchem Pharmaceuticals Pte Ltd, Medtronic Inc.

North America was the largest region in the viscosupplementation market in 2025. The regions covered in the viscosupplementation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viscosupplementation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the viscosupplementation market by increasing the cost of imported hyaluronic acid and related injectable components, leading to higher production and treatment costs. This disruption particularly affects single, three, and five injection types and regions heavily reliant on imports, such as North America and Europe. Hospitals and ambulatory surgical centers face cost pressures, while local manufacturing initiatives may see growth. Overall, tariffs are driving manufacturers to explore domestic sourcing and cost-efficient innovations.

The viscosupplementation market research report is one of a series of new reports that provides viscosupplementation market statistics, including viscosupplementation industry global market size, regional shares, competitors with a viscosupplementation market share, detailed viscosupplementation market segments, market trends and opportunities, and any further data you may need to thrive in the viscosupplementation industry. This viscosupplementation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Viscosupplementation is a process in which hyaluronic acid, a gel-like fluid, is injected directly into a joint. Synovial fluid, naturally present around joints, contains hyaluronic acid, which helps reduce friction during movement.

The primary types of viscosupplementation include single-injection, three-injection, and five-injection viscosupplementation. Single-injection viscosupplementation involves a single shot of hyaluronic acid injected directly into the diarthrodial joints of a person's knees, aimed at restoring the rheological properties of the synovial fluid, thereby providing anti-inflammatory and analgesic effects. Hyaluronic acid, including both standard and stabilized forms, can be derived from avian and non-avian sources. These treatments are used to manage various osteoarthritides, including knee osteoarthritis, hip osteoarthritis, and hand osteoarthritis, and are administered in settings such as hospitals, ambulatory surgical centers, and others.

The viscosupplementation market consists of revenues earned by entities by providing viscosupplementation therapy services such as plasma-rich platelet (PRP) injections and stem cell injections that are used in osteoarthritis (OA) treatment procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The viscosupplementation market also includes sales of hyaluronans and hylan injection preparations to provide viscosupplementation therapy services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.